>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
晚期非小细胞肺癌免疫治疗研究进展
作者:陈琪1  陆建1  郭金和2 
单位:1. 东南大学 医学院, 江苏 南京 210009;
2. 东南大学附属中大医院 介入与血管外科, 江苏 南京 210009
关键词:晚期非小细胞肺癌 免疫检查点抑制剂 免疫联合治疗 免疫相关不良事件 文献综述 
分类号:R734.2
出版年·卷·期(页码):2021·40·第四期(536-541)
摘要:

随着对肿瘤免疫逃避机制的了解,免疫检查点抑制剂不断被证明可用于晚期非小细胞肺癌一线及后线治疗。作者就免疫检查点抑制剂治疗机制、在晚期非小细胞肺癌治疗中的研究进展以及免疫相关不良事件进行综述,旨在为临床实践提供参考。

参考文献:

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[3] MOLINA J R, YANG P, CASSIVI S D, et al. Non-small cell lung cancer:epidemiology, risk factors, treatment, and survivorship[J]. Mayo Clin Proc, 2008, 83(5):584-594.
[4] ETTINGER D S, WOOD D E, AGGARWAL C, et al. NCCN guidelines insights:non-small cell lung cancer, version 1.2020[J]. J Natl Compr Canc Netw, 2019, 17(12):1464-1472.
[5] DOROSHOW D B, HERBST R S.Treatment of advanced non-small cell lung cancer in 2018[J]. JAMA Oncol, 2018, 4(4):569-570.
[6] WEI S C, DUFFY C R, ALLISON J P.Fundamental mechanisms of immune checkpoint blockade therapy[J]. Cancer Discov, 2018, 8(9):1069-1086.
[7] BORGHAEI H, PAZ-ARES L, HORN L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17):1627-1639.
[8] BRAHMER J, RECKAMP K L, BAAS P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2):123-135.
[9] HERBST R S, BAAS P, KIM D W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010):a randomised controlled trial[J]. Lancet, 2016, 387(10027):1540-1550.
[10] RITTMEYER A, BARLESI F, WATERKAMP D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer(OAK):a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066):255-265.
[11] RECK M, RODRIEZ-ABREU D, ROBINSON A G, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016, 375(19):1823-1833.
[12] MOK T, WU Y L, KUDABA I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042):a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019, 393(10183):1819-1830.
[13] SEZER A, KILICKAP S, GUMUS M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%:a multicentre, open-label, global, phase 3, randomised, controlled trial[J]. Lancet, 2021, 397(10274):592-604.
[14] LANGER C J, GADGEEL S M, BORGHAEI H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer:a randomised, phase 2 cohort of the open-label KEYNOTE-021 study[J]. Lancet Oncol, 2016, 17(11):1497-1508.
[15] GANDHI L, RODRIGUEZ-ABREU D, GADGEEL S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22):2078-2092.
[16] RODRIGUEZ-ABREU D, POWELL S F, HOCHMAIR M J, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC:protocol-specified final analysis from KEYNOTE-189[J]. Ann Oncol, 2021, 32(7):881-895.
[17] PAZ-ARES L, LUFT A, VICENTE D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21):2040-2051.
[18] ZHOU C, CHEN G, HUANG Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer(CameL):a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Respir Med, 2021, 9(3):305-314.
[19] YANG Y, ZHOU H, ZHANG L.Response to letter to the editor:efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC:a randomized, double-blind, phase 3 study(ORIENT-11)[J]. J Thorac Oncol, 2020, 15(12):e191-e192.
[20] LU S, LU Y, YU X, et al. 1263P Tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC[J]. Ann Oncol, 2020, 31(Suppl 4):S816-S817.
[21] ZHOU C, WU L, FAN Y, et al. LBA56 ORIENT-12:Sintilimab plus gemcitabine and platinum(GP) as first-line(1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer(sqNSCLC)[J]. Ann Oncol, 2020, 31(Suppl 4):S1186.
[22] WANG J, LU S, YU X, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer:a phase 3 randomized clinical trial[J]. JAMA Oncol, 2021, 7(5):709-717.
[23] ROBERT L, RIBAS A, HU-LIESKOVAN S.Combining targeted therapy with immunotherapy.Can 1+1 equal more than 2?[J]. Semin Immunol, 2016, 28(1):73-80.
[24] PROTO C, FERRARA R, SIGNORELLI D, et al. Choosing wisely first line immunotherapy in non-small cell lung cancer(NSCLC):what to add and what to leave out[J]. Cancer Treat Rev, 2019, 75:39-51.
[25] OXNARD G R, YANG J C, YU H, et al. TATTON:a multi-arm, phase Ⅰb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer[J]. Ann Oncol, 2020, 31(4):507-516.
[26] HELLMANN M D, CIULEANU T E, PLUZANSKI A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018, 378(22):2093-2104.
[27] RAMALINGAM S S, CIULEANU T E, PLUZANSKI A, et al. Nivolumab+ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer:three-year update from CheckMate 227 Part 1[J]. J Clin Oncol, 2020, 38(15 Suppl):9500.
[28] RECK M, CIULEANU T E, DOLS M C, et al. Nivolumab(NIVO)+ipilimumab(IPI)+2 cycles of platinum-doublet chemotherapy(chemo) vs 4 cycles chemo as first-line (1L) treatment(tx) for stage Ⅳ/recurrent non-small cell lung cancer(NSCLC):CheckMate 9LA[J]. J Clin Oncol, 2020, 38(15 Suppl):9501.
[29] ERINJERI J P, FINE G C, ADEMA G J, et al. Immunotherapy and the interventional oncologist:challenges and opportunities-a society of interventional oncology white paper[J]. Radiology, 2019, 292(1):25-34.
[30] CHANG X, LU X, GUO J, et al. Interventional therapy combined with immune checkpoint inhibitors:Emerging opportunities for cancer treatment in the era of immunotherapy[J]. Cancer Treat Rev, 2019, 74:49-60.
[31] DENG L, LIANG H, BURNETTE B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice[J]. J Clin Invest, 2014, 124(2):687-695.
[32] HERRERA F G, BOURHIS J, COUKOS G.Radiotherapy combination opportunities leveraging immunity for the next oncology practice[J]. CA Cancer J Clin, 2017, 67(1):65-85.
[33] SHI L, CHEN L, WU C, et al. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor[J]. Clin Cancer Res, 2016, 22(5):1173-1184.
[34] DEIPOLYI A R, BROMBERG J F, ERINJERI J P, et al. Abscopal effect after radioembolization for metastatic breast cancer in the setting of immunotherapy[J]. J Vasc Interv Radiol, 2018, 29(3):432-433.
[35] ERINJERI J P, THOMAS C T, SAMOILIA A, et al. Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10[J]. J Vasc Interv Radiol, 2013, 24(8):1105-1112.
[36] YIN J, DONG J, GAO W, et al. A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage Ⅳ nonsmall cell lung cancer[J]. Medicine(Baltimore), 2018, 97(44):e13112.
[37] DUFFY A G, ULAHANNAN S V, MAKOROVA-RUSHER O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3):545-551.
[38] WANG S, ZHANG J, MENG F J, et al. Combination of pembrolizumab and (125) I attenuates the aggressiveness of non-small cell lung cancer[J]. Oncol Lett, 2020, 19(6):4142-4150.
[39] BACKLUND M, FREEDMAN J.Microwave ablation and immune activation in the treatment of recurrent colorectal lung metastases:a case report[J]. Case Rep Oncol, 2017, 10(1):383-387.
[40] YAKKALA C, CHIANG C L L, KANDALAFT L, et al. Cryoablation and immunotherapy:an enthralling synergy to confront the tumors[J]. Front Immunol, 2019, 10:2283.
[41] RODRIGUEZ-ABREU D, JOHNSON M L, HUSSEIN M A, et al. Primary analysis of a randomized, double-blind, phase Ⅱ study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab(atezo) versus placebo plus atezo as first-line(1L) treatment in patients with PD-L1-selected NSCLC(CITYSCAPE)[J]. J Clin Oncol, 2020, 38(15 Suppl):9503.
[42] POSTOW M A, SIDLOW R, HELLMANN M D.Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2):158-168.
[43] BERTRAND A, KOSTINE M, BARNETCHE T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies:systematic review and meta-analysis[J]. BMC Med, 2015, 13:211.
[44] WANG Y, ZHOU S, YANG F, et al. Treatment-related adverse events of pd-1 and pd-l1 inhibitors in clinical trials:a systematic review and Meta-analysis[J]. JAMA Oncol, 2019, 5(7):1008-1019.
[45] SHOUSHTARI A N, FRIEDMAN C F, NAVID-AZARBAIJANI P, et al. Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma[J]. JAMA Oncol, 2018, 4(1):98-101.
[46] WANG D Y, SALEM J E, COHEN J V, et al. Fatal toxic effects associated with immune checkpoint inhibitors:a systematic review and Meta-analysis[J]. JAMA Oncol, 2018, 4(12):1721-1728.
[47] CURRY J L, TETZLAFFM T, NAGARAJAN P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy[J]. J Cutan Pathol, 2017, 44(2):158-176.
[48] MIN L C, LI S, TRAN D C, et al. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes:a retrospective case-control study[J]. J Am Acad Dermatol, 2018, 79(6):1047-1052.
[49] PUZANOV I, DIAB A, ABDALLAH K, et al. Managing toxicities associated with immune checkpoint inhibitors:consensus recommendations from the Society for Immunotherapy of Cancer(SITC) Toxicity Management Working Group[J]. J Immunother Cancer, 2017, 5(1):1-28.
[50] ABU-SBEIH H, ALI F S, ALSAADI D, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis:a multi-center study[J]. J Immunother Cancer, 2018, 6(1):1-11.
[51] HAANEN J, CARBONNEL F, ROBERT C, et al. Management of toxicities from immunotherapy:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4):v264-v266.
[52] ZHANG L, JONES-O'CONNOR M, AWADALLA M, et al. Cardio-toxicity of immune checkpoint inhibitors[J]. Curr Treat Options Cardiovasc Med, 2019, 21(7):1-17.
[53] SIU L L, EVEN C, MESIA R, et al. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-Low/Negative recurrent or metastatic HNSCC:the phase 2 CONDOR randomized clinical trial[J]. JAMA Oncol, 2019, 5(2):195-203.
[54] RIZVI N A, HELLMANN M D, SNYDER A, et al. Cancer immunology.Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348(6230):124-128.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 343117 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364